HER2-targeted therapy showed durable and clinically meaningful results for patients with rare bile duct cancers

Researchers identified promising therapeutic targets for KRAS-mutant cancers and kidney cancers 

Study provides insights into AI models for genomic analysis and clinical decision-making

Researchers uncovered how DNA shape and rigidity affects gene expression

A new study finds that intrusive thoughts and psychotic-like experiences among new parents are far more common than previously thought.

The research reveals the mental health challenges faced by both mums and dads in the first year after childbirth.

The team hope their work will lead to greater awareness, early screening, and accessible mental health support for all parents, not just those with diagnosed conditions.

MIT chemists synthesized a fungal compound that holds promise for treating brain cancer. Early studies find derivatives of the compound, verticillin A, can kill certain glioma cells.

Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope to ovarian cancer patients who do not respond to existing treatments. Conducted entirely at the University of Colorado Anschutz, this research has advanced from the laboratory to a Phase 1 clinical trial on the campus.

The findings, published today in Cancer Research Communications, outline a promising strategy that combines a PARP inhibitor, a targeted drug used to treat certain types of ovarian cancer, with a novel therapy, SM08502, to attack cancer from two directions. This innovative approach boosts the effectiveness of the treatment, even for patients who are no longer responding to PARP inhibitor therapy. “This achievement exemplifies true bench-to-bedside innovation entirely done at CU Anschutz,” said the paper’s first author Bradley Corr, MD, associate professor and director of clinical research in gynecologic oncology at CU Anschutz. “To the best of our knowledge, this is the first clinical trial to successfully combine these classes of drugs. While the concept has been discussed before, no one has moved it into the clinic until now. That’s what makes this approach truly novel.”